The safety and efficacy of umbilical cord blood mononuclear cells in individuals with spastic cerebral palsy: a randomized double-blind sham-controlled clinical trial

Table 2 Baseline characteristic data

Variables	Control group	UCB-MNC group	P-value
Gender, n (%)
Female	17 (47.2)	25 (69.45)
Male	19(52.8)	11 (30.55)	0.11
Age (months)
Mean ± SD	102.50 ± 29.91	112.51 ± 36.59	0.16
Weight (kg)
Mean ± SD	17.32 ± 7.21	19.63 ± 8.51	0.19
Type of cerebral palsy, n (%)
Spastic quadriplegia	32 (88.9)	29 (80.0)
Spastic diplegia	4 (11.1)	7 (20.0)	0.30
GMFCS
II/ III/ IV/V	4/4/11/17	6/5/11/14	0.25
GMFM-66
Mean ± SD	66.30 ± 50.75	73.38 ± 49.15	0.45
MAS
Mean ± SD	3.16 ± 0.97	2.91 ± 1.12	0.21
PEDI Self-care
Mean ± SD	21.77 ± 16.15	27.58 ± 18.63	0.67
PEDI Mobility
Mean ± SD	16.07 ± 14.01	22.11 ± 15.16	0.20
PEDI Social function
Mean ± SD	26.63 ± 18.76	39.82 ± 18.42	0.67
CP-QOL
Mean ± SD	369.8 ± 56.2	382.85 ± 63.02	0.36
FA corticospinal tract
Mean ± SD	0.43 ± 0.06	0.45 ± 0.07	0.25
MD corticospinal tract^a
Mean ± SD	0.96 ± 0.07	0.94 ± 0.06	0.24
FA posterior thalamic radiation
Mean ± SD	0.31 ± 0.04	0.35 ± 0.05	0.30
MD posterior thalamic radiation^a
Mean ± SD	1.06 ± 0.12	1.06 ± 0.08	0.98

UCB-MNC Umbilical cord blood mononuclear cell, SD Standard deviation, GMFCS Growth motor classification system, GMFM Growth motor function measurement, PEDI Pediatric evaluation of disability inventory, CP-QOL Cerebral palsy quality of life, FA Fractional anisotropy, MD Mean diffusivity
^aThe results should be divided by 1000

ISSN: 1471-2377